I don't have much time for analysts' reports (unless they tell me what I want to hear
) however I note the three analyst reports on the LaserBond website all list LBL as a buy, albeit with reduced price targets.
Curren & Co. is a
buy, with a target price reduced from $1.25 in August, to
$1.00 now
Cannacord Genuity is a
buy, with a target price reduced from $1.10 to
$0.85 now
PAC Partners is a
buy, (initiating coverage) with a target price of
$0.62https://www.laserbond.com/investor-relations/analyst-reports/I'm convinced these prices are plucked from thin air. The price today is
$0.39.
The theme I'm seeing across the three reports is increased costs, which will hopefully fuel greater revenue and profit, a geographic presence across Australia to allow access to many different markets, and valuable IP. However, costly investments in people and equipment won't bear fruit until next year.
I fear the share price will stagnate until at least August's FY results, unless a surprise catalyst for a re-rate occurs.
@Grasshopper59 Thank you for your recent posts. You might not be on the board as such, but it seems management are aware of your contributions here, and anything you write is surely being seen and considered by the executive team. You're not just some anonymous guy on the internet with an opinion. And you can no doubt share your thoughts with Wayne with a phone call or e-mail. So, your posts are not going to waste. I hope, as I wrote in a previous post, that a unique role, such as heading the US expansion site, can be found for your obvious talent and experience.
(20min delay)